Reviving the microcirculation; the protective role of SGLT2 inhibitors in counteracting capillary rarefaction
Open Access
- 21 June 2026
- journal article
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 15 (2) , e12876
Abstract
Capillary rarefaction, as the loss of microvascular density and architecture, is a hallmark of chronic tissue hypoxia seen in diabetes, hypertension, and various forms of chronic kidney and heart disease. It promotes inflammation, fibrosis, and eventual loss of organ function by diminishing oxygen delivery, nutrient exchange, and waste removal. In diabetic nephropathy, intrarenal hypoxia accelerates capillary rarefaction, creating a destructive feedback loop of progressive renal impairment. The restoration of microvascular integrity by SGLT2 inhibitors encompasses a series of glucose-independent actions, involving both metabolic and cellular signaling pathways. These compounds modulate the renal and systemic microcirculation through several key lines. Preclinical data demonstrate improved endothelial function, characterized by enhanced nitric oxide production, decreased oxidative stress, and normalized mitochondrial homeostasis. These drugs stimulate angiogenic pathways and endothelial cell viability, directly promoting the regeneration of microvessels and counteracting rarefaction. These agents have also been shown to attenuate inflammation within the microvasculature, reducing cytokine-driven vascular injury and remodeling. In both animal studies and early-phase clinical investigations, SGLT2 inhibitors foster improved vasodilation and hemodynamic stability, which are crucial to maintaining capillary networks.Keywords
This publication has 63 references indexed in Scilit:
- Redefining SGLT2 inhibitors through cytoprotective mechanismsEuropean Journal of Pharmacology, 2026
- SGLT2 inhibitors and cardiac fibrosis: A comprehensive reviewCurrent Problems in Cardiology, 2025
- SGLT-2 inhibitors as novel treatments of multiple organ fibrosisHeliyon, 2024
- Sodium–Glucose Cotransporter 2 Inhibitors Influence Skeletal Muscle Pathology in Patients with Heart Failure and Reduced Ejection FractionEuropean Journal of Heart Failure, 2024
- Signaling pathways and intervention for therapy of type 2 diabetes mellitusMedcomm, 2023
- Sodium–glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanismsPharmacological Reports, 2022
- SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?Current Heart Failure Reports, 2021
- Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protectionInternational Journal of Cardiology Hypertension, 2020
- Renal Effects of Sodium-Glucose Co-Transporter InhibitorsThe American Journal of Cardiology, 2019
- Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's diseaseCellular Signalling, 2014